scholarly journals Psycho-oncology service provisions for hospitalised cancer patients before and during the COVID-19 pandemic in an oncology centre in eastern India

2021 ◽  
Vol 15 ◽  
Author(s):  
Arnab Mukherjee ◽  
Meheli Chatterjee ◽  
Shrestha Chattopadhyay ◽  
Chitralekha Bhowmick ◽  
Archisman Basu ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Eastern India ◽  
Oncology Service ◽  
Oncology Centre ◽  
Service Provisions

Short term outcome for colorectal cancer patients undergoing surgery in Tertiary care center in Eastern India

2021 ◽  
Vol 47 (2) ◽  
pp. e50-e51
Author(s):  
Abhitesh Singh ◽  
Anshul Jain ◽  
Dillip Muduly ◽  
Mahesh Sultania ◽  
Jyoti Ranjan Swain ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Care Center ◽  
Tertiary Care ◽  
Tertiary Care Center ◽  
Eastern India ◽  
Short Term ◽  
Term Outcome ◽  
Short Term Outcome ◽  
Colorectal Cancer Patients

scholarly journals COVID-19 Vaccine Safety in Cancer Patients: A Single Centre Experience

Cancers ◽  
2021 ◽  
Vol 13 (14) ◽  
pp. 3573
Author(s):  
Alfred Chung Pui So ◽  
Harriet McGrath ◽  
Jonathan Ting ◽  
Krishnie Srikandarajah ◽  
Styliani Germanou ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Safety Data ◽  
Vaccine Safety ◽  
Phase Iii ◽  
Solid Malignancy ◽  
Common Grade ◽  
Phase Iii Trials ◽  
Oncology Care ◽  
Grade 3 ◽  
Oncology Centre

Emergency approval of vaccines against COVID-19 provides an opportunity for us to return to pre-pandemic oncology care. However, safety data in cancer patients is lacking due to their exclusion from most phase III trials. We included all patients aged less than 65 years who received a COVID-19 vaccine from 8 December 2020 to 28 February 2021 at our London tertiary oncology centre. Solicited and unsolicited vaccine-related adverse events (VRAEs) were collected using telephone or face-to-face consultation. Within the study period, 373 patients received their first dose of vaccine: Pfizer/BioNTech (75.1%), Oxford/AstraZeneca (23.6%), Moderna (0.3%), and unknown (1.1%). Median follow-up was 25 days (5–85). Median age was 56 years (19–65). Of the patients, 94.9% had a solid malignancy and 76.7% were stage 3–4. The most common cancers were breast (34.0%), lung (13.4%), colorectal (10.2%), and gynaecological (10.2%). Of the patients, 88.5% were receiving anti-cancer treatment (36.2% parenteral chemotherapy and 15.3% immunotherapy), 76.1% developed any grade VRAE of which 2.1% were grade 3. No grade 4/5 or anaphylaxis were observed. The most common VRAEs within 7 days post-vaccination were sore arm (61.7%), fatigue (18.2%), and headaches (12.1%). Most common grade 3 VRAE was fatigue (1.1%). Our results demonstrate that COVID-19 vaccines in oncology patients have mild reactogenicity.

scholarly journals Overall survival and disease-free survival in breast cancer patients treated at the Oncology Centre in Bydgoszcz – analysis of more than six years of follow-up

2015 ◽  
Vol 4 ◽  
pp. 284-289 ◽  
Author(s):  
Tomasz Nowikiewicz ◽  
Magdalena Wiśniewska ◽  
Michał Wiśniewski ◽  
Marta Biedka ◽  
Iwona Głowacka ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Cancer Patients ◽  
Disease Free Survival ◽  
Breast Cancer Patients ◽  
Free Survival ◽  
Oncology Centre ◽  
Disease Free

scholarly journals AWARENESS REGARDING DIFFERENT ASPECTS OF CANCER AND ACCESS TO THE TREATMENTS OF CANCER OF THE PATIENTS ATTENDING AT A PIONEER REGIONAL CANCER CENTRE OF EASTERN INDIA

2021 ◽  
Vol 5 (2) ◽  
Author(s):  
Deepa Chakrabarti ◽  
Shubhra Ray ◽  
Syamsundar Mandal
Keyword(s):  
Cancer Patients ◽  
Family Income ◽  
Drop Out ◽  
Eastern India ◽  
Cancer Treatments ◽  
Duration Of Symptoms ◽  
Cancer Centre ◽  
The Mean ◽  
Regional Cancer Centre

Cancer patients are prone to be non-compliant to treatment and follow-up. Many studies have been conducted so far regarding knowledge of cancers among the community people. However, not many studies have looked into knowledge of treatments, toxicities due to treatments and importance of follow-up in India. As a result of that no educational intervention programme could be initiated to improve treatment and follow-up compliance among the cancer patients. Thus the present study aimed at assessing awareness of different aspects of cancer treatments and assessing the accesses to the treatments among the patients attended at regional cancer centre of eastern India. Methods: The study was conducted on 858 patients selected randomly from 9406 patients attended at Out Patient Door (OPD) of Chittaranjan National Cancer Institute (CNCI) during the period 1st January 2019 – 31st December 2019. Result: The study aimed at assessing the level of awareness regarding cancer and the access to the treatments of the patients. The mean (mean±s.d.) age of the patients was 50.56±14.94 years with range 2 – 89 years and the median age was 52 years. The sex ratio of the patients was (Male : Female) was 1.0 : 1.3.  71.4% of the patients were with monthly family income ? INR 2000. (p<0.0001) as a result of that monthly per capita income 56.5% of the patients was ? INR 500. (p<0.0001). 56.2% of the respondents opined that cancer is curable but 40.7% of them had no idea (p=0.034). The mean (mean±s.d.) duration of symptoms of the patients was 8.64±10.23 months with range 0.20 – 96 months and the median was 6 months. The mean (mean±s.d.) time to first consult with any doctor after onset of symptoms of the patients was 11.92±11.22 months with range 0.20 – 96 months and the median was 9 months. The mean (mean±s.d.) distance of residence from CNCI of the patients was 175.14±169.06 km with range 1 – 800 km and the median was 120 km. 70.2% of them had no place to stay with free of cost around CNCI (p<0.0001). 70.3% of them had no idea about time to completion of treatments of cancer. 91.7% of them had no idea about type of treatment generally required to treat cancer (p<0.0001). 97.8% and 96.7% of them had no knowledge about radiotherapy and chemotherapy respectively (p<0.0001). 49.4% of the patients had no idea about requirement of follow-up / check-up after the completion of treatments but 46.5% believed that follow-up / check-up is required after the completion of treatments (p=0.77). Conclusions: From the results of the study it revealed that majority of the cancer patients attending cancer hospitals had no idea about the type of treatments required and its inevitable side effects in most of the cases during treatments which may enforce the patients to be non-compliance of treatments. Moreover, majority of them were reporting late after the onset of symptoms which leads to late presentation by the patients with advancement of disease. Counseling with the patients regarding different aspects of cancer treatments at the very first day of attendance in a cancer hospital will be effective to reduce the drop out during treatments and follow-up. Keywords: cancer awareness – education interventional programme – access to treatments – late reporting

scholarly journals The Waiting Time of Prostate Cancer Patients in Poland

2019 ◽  
Vol 16 (3) ◽  
pp. 342 ◽  
Author(s):  
Karolina Osowiecka ◽  
Sergiusz Nawrocki ◽  
Marcin Kurowicki ◽  
Monika Rucinska
Keyword(s):  
Prostate Cancer ◽  
Radiation Therapy ◽  
Cancer Patients ◽  
Median Time ◽  
Waiting Time ◽  
Common Reason ◽  
Histopathological Diagnosis ◽  
Place Of Residence ◽  
Oncology Centre ◽  
The Impact

Background: Prostate cancer is the second most common reason of mortality due to cancer among men in Poland. The study aimed to determine the waiting time for diagnosis and treatment of prostate cancer. Methods: The study was carried out on patients treated for prostate cancer from May 2014 to February 2015 at five oncological centres in Poland. The median waiting time was measured from the time cancer was suspected to the histopathological diagnosis (SDI), from the cancer suspicion to the start of treatment (STI) and from the diagnosis to the start of treatment (DTI). Results: 123 males treated for prostate cancer were included for analysis. The median time for SDI, STI and DTI was 7.7, 18.7 and 8.7 weeks, respectively. Place of residence was the only factor which influenced STI (p = 0.003). For patients, who started treatment with radiation therapy DTI was longer than for other patients (p < 0.001). Conclusions: Median times of STI, SDI and DTI for prostate cancer patients in Poland are similar to the intervals described in other countries. Patients, who lived further from an oncology centre waited longer for treatment. The impact of waiting time in the case of prostate cancer on improving the prognosis is still unclear.

Sign in / Sign up

Export Citation Format

Share Document